Quick verdict: CCEP vs MDLZ in 2026

In this ccep vs mdlz stock comparison 2026, Mondelez International (MDLZ) exhibits stronger revenue growth and higher analyst conviction, while Coca-Cola Europacific Partners (CCEP) offers a more attractive valuation based on P/E and superior profitability margins. CCEP also presents a higher target price upside, though MDLZ’s discounted cash flow model suggests greater intrinsic value potential. Not investment advice.

CCEP vs MDLZ: key metrics side by side

Full side-by-side comparison of CCEP and MDLZ across valuation, profitability, growth and analyst sentiment. Data updated 2026-05-07.

CCEP vs MDLZ valuation comparison

Understanding the ccep vs mdlz fundamentals and valuation reveals distinct profiles. Coca-Cola Europacific Partners (CCEP) currently trades at a P/E ratio of 18.46x, which is significantly lower than Mondelez International’s (MDLZ) P/E ratio of 30.25x. This suggests that CCEP is more attractively valued on an earnings multiple basis, indicating investors are paying less for each dollar of CCEP’s earnings compared to MDLZ. When looking at price-to-book (P/B), MDLZ holds an edge with a P/B of 3.07x against CCEP’s 4.57x, implying that MDLZ’s stock price is lower relative to its book value of assets.

However, a deeper look at valuation via discounted cash flow (DCF) models presents a different perspective. CCEP has a DCF calculated upside of +49.5%, suggesting substantial undervaluation compared to its intrinsic value. MDLZ, on the other hand, shows an even more striking DCF upside of +113.7%. This indicates that despite its higher P/E, MDLZ’s future cash flow generation, when discounted back to the present, implies a much greater potential for appreciation. Therefore, while CCEP appears cheaper on a traditional P/E basis, MDLZ’s DCF analysis points to a potentially greater long-term value proposition if its future growth projections materialize.

CCEP vs MDLZ growth comparison

In terms of top-line expansion, Mondelez International (MDLZ) demonstrates stronger momentum compared to Coca-Cola Europacific Partners (CCEP). MDLZ reported a year-over-year revenue growth of +5.8%, nearly double CCEP’s +2.3%. This suggests that MDLZ is currently more effective at expanding its sales base and capturing market share in the consumer defensive sector. For investors prioritizing companies with higher sales growth rates, MDLZ clearly stands out as the leader in this aspect, indicating stronger operational scaling and market penetration.

Despite CCEP’s slower revenue growth, it exhibits superior efficiency in converting sales into profits. CCEP boasts a net margin of 9.29% and an EBITDA margin of 16.39%, both significantly higher than MDLZ’s net margin of 6.65% and EBITDA margin of 12.18%. This implies that while MDLZ is growing its revenue faster, CCEP manages its costs and operations more effectively, leading to a larger portion of its revenue flowing down to its bottom line. Therefore, an investor must weigh whether faster revenue growth (MDLZ) or higher operational efficiency and profitability (CCEP) is more critical to their investment strategy.

CCEP vs MDLZ profitability

Coca-Cola Europacific Partners (CCEP) generally outperforms Mondelez International (MDLZ) in several key profitability metrics. CCEP’s net margin stands at 9.29%, indicating that it converts a larger percentage of its revenue into net income compared to MDLZ’s 6.65%. This stronger net margin suggests superior cost management and operational efficiency within CCEP. Similarly, CCEP’s EBITDA margin of 16.39% is considerably higher than MDLZ’s 12.18%, further underscoring CCEP’s ability to generate more earnings before interest, taxes, depreciation, and amortization from its sales.

When evaluating how efficiently these companies generate cash from their operations, CCEP also holds a significant advantage. CCEP’s free cash flow (FCF) yield is an impressive 6.02%, nearly twice that of MDLZ’s 3.27%. This higher FCF yield means CCEP generates substantially more cash relative to its market capitalization, which can be reinvested in the business, used for debt reduction, or returned to shareholders. For both companies, the Return on Equity (ROE) is currently not available, preventing a direct comparison of shareholder equity efficiency. However, based on net margins, EBITDA margins, and FCF yield, CCEP demonstrates stronger overall profitability and cash generation capabilities.

Analyst ratings: CCEP vs MDLZ

The analyst community shows a positive consensus for both Coca-Cola Europacific Partners (CCEP) and Mondelez International (MDLZ), with both stocks garnering “Buy” ratings. However, the degree of conviction and implied upside varies. MDLZ is covered by 41 analysts, with a substantial 75.6% recommending a “Buy.” Their consensus price target for MDLZ is $67, representing a +9.2% upside from its current price of $61.33. This widespread positive sentiment suggests a strong belief in MDLZ’s continued performance and growth trajectory among a larger pool of analysts.

In contrast, CCEP is covered by 28 analysts, with 53.6% giving it a “Buy” rating. While still positive, this percentage is lower than MDLZ’s. However, the implied upside from CCEP’s consensus price target of $110.6 is +17.7% from its current price of $93.9643. This is nearly double the target upside predicted for MDLZ. Therefore, while MDLZ enjoys broader and slightly stronger positive sentiment, CCEP offers a significantly higher implied return based on analyst price targets, potentially indicating greater perceived undervaluation or future catalysts for growth in the eyes of the analysts covering it.

Should I buy CCEP or MDLZ stock in 2026?

Deciding whether should i buy ccep or mdlz stock in 2026 depends heavily on an investor’s specific objectives and risk tolerance, as both companies offer distinct advantages within the consumer defensive sector. For growth-oriented investors, Mondelez International (MDLZ) appears to be the more compelling choice. With a revenue growth of +5.8% year-over-year, MDLZ demonstrates stronger top-line momentum compared to CCEP’s +2.3%. This suggests MDLZ is better positioned to expand its market presence and deliver higher sales growth in the near to medium term. Additionally, MDLZ has higher analyst conviction with 75.6% buy ratings from 41 analysts, which may indicate a more favorable outlook for its growth prospects.

For value investors, Coca-Cola Europacific Partners (CCEP) presents a more attractive proposition. CCEP trades at a lower P/E ratio of 18.46x compared to MDLZ’s 30.25x, suggesting it is currently undervalued relative to its earnings. Furthermore, CCEP boasts superior profitability metrics, including a net margin of 9.29% (vs. MDLZ’s 6.65%) and an EBITDA margin of 16.39% (vs. MDLZ’s 12.18%). Its higher Free Cash Flow yield of 6.02% (vs. MDLZ’s 3.27%) further solidifies its position as a strong cash generator, making it potentially more appealing for investors seeking companies with robust underlying financial health at a more reasonable price. While MDLZ offers a higher DCF upside, CCEP’s current valuation multiples and strong profitability metrics make it an intriguing choice for value seekers.

When considering income, both CCEP and MDLZ offer very modest dividend yields, typical for many growth-focused companies that prefer to reinvest earnings. MDLZ has a slight edge with a dividend yield of 0.03% compared to CCEP’s 0.02%. Investors primarily focused on generating significant income from dividends might find both options less appealing than higher-yielding alternatives in the market. However, for those looking for a blend of growth or value within the consumer defensive segment, and where dividends are a secondary consideration, MDLZ offers slightly more in terms of yield. Ultimately, the choice between CCEP and MDLZ in 2026 hinges on whether an investor prioritizes MDLZ’s stronger growth momentum and analyst favorability, or CCEP’s more attractive valuation, superior margins, and higher target price upside. This is not investment advice.

More CCEP and MDLZ comparisons

CCEP full stock analysis · MDLZ full stock analysis · All stock comparisons

FAQ: CCEP vs MDLZ